Abstract
The recent COVID-19 epidemic demonstrated the need and importance of epidemic models as a tool for policy-making during times of uncertainty, allowing the decision-makers to test different intervention techniques and scenarios. Furthermore, tools such as large-scale contact tracing became technologically feasible for the first time. While large-scale agent-based simulations are nowadays part of the toolboxes, good analytical models allow for much faster testing of scenarios. Unfortunately, good models that consider contact tracing and quarantine, and allow for different degree distributions do not exist. To overcome these shortcomings of existing models we propose a new simple compartmental model that integrates quarantine and contact tracing into the SIR compartmental models with arbitrary degree distribution of nodes to better understand the dynamics of the disease under various parameters of intervention and contagion. Consequently, we analytically derive the epidemic threshold as a function of the degree distribution and the model parameters when both quarantine and contact tracing are used. Simulation results demonstrate and quantify the benefits of quarantine and contact tracing and show the effectiveness of such measures over a large range of epidemic parameters.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors